Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1425

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 9A
Chunk 1425
---

Patents, net consist of the following:

    Schedule of patents, net 

    March 31, 2025  
    March 31, 2024 
  
    Issued patents 
    $157,442  
    $157,442 
  
    Accumulated amortization 
     (156,892) 
     (156,342)
  
    Patents, net 
    $550  
    $1,100 

Amortization expense for our capitalized issued
patents for each of the fiscal years ended March 31, 2025 and 2024 was $550. As only one capitalized patent remains to be amortized, future
amortization expense on patents is estimated to be approximately $550 per year based on the estimated life of the patent. The weighted
average remaining life of our remaining capitalized patent is approximately 1.0 year.

4. EQUITY TRANSACTIONS

REVERSE
STOCK SPLIT

Effective as of
the close of business on June 6, 2025 with an effective trading date of  June 9, 2025, we
effected a 1-for-8 reverse
stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our
stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to
the next whole share. Authorized common stock remained at 60,000,000 shares
following the stock split. The accompanying consolidated financial statements and accompanying notes have been retroactively revised
to reflect such reverse stock split as if it had occurred on April 1, 2023. All shares and per share amounts have been revised
accordingly.

WARRANT
INDUCEMENT 

In March 2025, the Company
entered into a warrant inducement agreement resulting in the issuance of 1,550,000 new warrants and the modification of 775,000 existing
warrants. The fair value of the new warrants and the incremental fair value from the modification totaled $4,612,862 which was recorded
as a non-cash inducement expense in other expense and reflected as an increase to additional paid-in capital.

ISSUANCES OF COMMON STOCK AND WARRANTS

Equity Transactions in the Fiscal Year Ended March 31, 2025.

March 2025 Warrant-Based
Financing

On March 16, 2025